Physician profile
Stephen Craig Ellen
NPI 1700825791
$1,400,014.93
in general payments reported to CMS, 2019-2025
23 companies · $347K in 2025
The $347K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167K · 2020: $124K · 2021: $117K · 2022: $188K · 2023: $224K · 2024: $233K · 2025: $347K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $503K · Consulting Fee: $104K · Travel and Lodging: $95K · Honoraria: $82K · Food and Beverage: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,813 · Education: $14.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $502,517.50 |
| Consulting Fee | $104,115.50 |
| Travel and Lodging | $94,750.77 |
| Honoraria | $81,540.50 |
| Food and Beverage | $18,103.60 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,812.50 |
| Education | $14.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $621,466.28 | 2021-2025 | |
| Allergan, INC. | $251,733.48 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224,698.70 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $185,028.89 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $44,734.72 | 2021-2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $21,794.33 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $14,024.47 | 2019-2024 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $11,785.47 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,797.07 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $7,492.50 | 2023 | Quviviq |
| Eisai INC. | $6,861.69 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $1,055.04 | 2019-2021 | |
| Neos Therapeutics, Lp | $180.98 | 2019 | |
| Merck Sharp & Dohme LLC | $77.47 | 2019 | |
| Ironshore Pharmaceuticals INC. | $65.41 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $53.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.28 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $35.89 | 2019-2020 | |
| Corium, LLC | $20.26 | 2022 | |
| Bausch Health US, LLC | $19.35 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.87 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $13.50 | 2019 | |
| Alfasigma USA, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ellen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.